Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-08-30
2005-08-30
Harris, Alana M. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007200, C435S007210, C435S007230, C436S063000, C436S064000, C436S086000, C436S164000, C530S300000, C530S350000, C530S386000, C530S387100, C530S387300, C530S387700, C530S387900, C530S388100, C530S388240, C530S388250, C530S389100, C530S389300, C530S391100, C530S391300
Reexamination Certificate
active
06936424
ABSTRACT:
The invention provides a wide range of methods and compositions for detecting and treating breast cancer in an individual. Specifically, the invention provides target breast cancer-associated proteins, which permit a rapid detection, preferably before metastases occur, of breast cancer. The target breast cancer-associated protein may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of breast cancer in an individual. In addition, the invention provides methods utilizing the breast cancer-associated proteins either as targets for treating breast cancer or as indicators for monitoring the efficacy of such a treatment.
REFERENCES:
patent: 5342764 (1994-08-01), Johnson et al.
patent: 5561222 (1996-10-01), Keene et al.
patent: 5719060 (1998-02-01), Hutchens et al.
patent: 5792664 (1998-08-01), Chait et al.
patent: 5876937 (1999-03-01), Sillekens
patent: 5962242 (1999-10-01), Klug
patent: 6020135 (2000-02-01), Levine et al.
patent: 6197525 (2001-03-01), Yao et al.
patent: 6225047 (2001-05-01), Hutchens et al.
patent: 6287521 (2001-09-01), Quay et al.
patent: 6410692 (2002-06-01), Stevens
patent: 2002/0081659 (2002-06-01), Rosen et al.
patent: 720626 (1998-02-01), None
patent: 196 32 521 (1998-02-01), None
patent: 0 460 607 (1991-11-01), None
patent: WO 98/42725 (1998-01-01), None
patent: WO 98/07036 (1998-02-01), None
patent: WO 99/39204 (1999-08-01), None
patent: WO 01/36470 (2001-05-01), None
patent: WO 01/36470 (2001-05-01), None
patent: WO 01/36977 (2001-05-01), None
patent: WO 01/36977 (2001-05-01), None
Adams et al. Detection of Mr 24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies. Cancer Research 43(9): 4297-4301, 1983.
GenCore databases, Sequence alignment between SEQ ID NO: 1 and sequence 687 of US Paten Application 2002/0081659, Jun. 2002.
Bringmann et al., (1983) “5'-Terminal Caps of snRNAs Are Accessible for Reaction with 2,2,7-Trimethylguanosine-specific Antibody in Intact snRNPs*,”J. Biol. Chem, 258(5): 2745-2747.
Brown et al., (2001) “Hypoxia and oxidation stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer,”Breast Cancer Res., 3(5): 323-327.
Casciola-Rosen et al., (1994) “Autoantigens Targeted in Systemic Lupus Erythematosus Are Clustered in Two Populations of Surface structures on Apoptotic Keratinocytes,”J. Exp. Med., 179: 1317-1330.
Craft et al., (1988) “The U2 Small Nuclear Ribonucleoprotein Particle as an Autoantigen: Analysis with Sera from Patients with Overlap Syndromes,”J. Clin. Invest., 81: 1716-1724.
El-Hefnawy et al., (2004) “Characterization of Amplifiable, Circulating RNA in Plasma and its Potential as a Tool for Cancer Diagnostics,”Clin. Chem., 50(3):564-573.
Ochs et al., (1994) “Coiled bodies in the nucleolus of breast cancer cells,”J. Cell Sci., 107: 385-399.
Utz, et al., (2000) “Death, autoantigen modificaitons, and tolerance,”Arthritis Res., 2:101-114.
Will et al., (2002) “Characterization of novel SF3B and 17S U2 snRNP proteins, including a human Prp5p homologue and SF3b DEAD-box protein,”EMBO J., 21: 4978-4988.
Aleynik et al., “Increased circulating products of lipid peroxidation in patients with alcoholic liver disease,”Alcohol Clin. Exp. Res., 22(1):192-196 (Feb. 1998).
Chong et al., “Protein profiles and identification of high performance liquid chromatography isolated proteins of cancer cell lines using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry,”Rapid Commun. Mass. Spectrom., 12(24):1986-1993 (1998).
Clements et al., “Biochemical characterization of patients and prenatal diagnosis of sialic acid storage disease for three families,”J. Inherit. Metab. Dis., 11(1):30-44 (1988).
Cross et al., “The trans-spliceosomal U2 snRNP protein 40K ofTrypanosoma brucei: cloning and analysis of functional domains reveals homology to a mammalian snRNP protein,”The EMBO Journal, 12(3):1239-1248 (1993).
Davies, H., “ProteinChip™ Case Study: Identification of a Novel Ligand,” http://www.ciphergen.com, (Jun. 16, 1999).
“Discovery of Protein Biomarkers and ‘Phenomic Fingerprints’ Using SELDI ProteinChip™ System,” http:www.ciphergen.com, downloaded Jan. 18, 2000.
Fury et al., “Thirteen Anti-Sm Monoclonal Antibodies Immunoprecipitate the Three Cytoplasmic snRNP Core Protein Precursors in Six Distinct Subsets,”Journal of Autoimmunity, 12:91-100 (1999).
Gottschalk et al., “Identification by mass spectrometry and functional analysis of novel proteins of the yeast [U4/U6-U5] tri-snRNP,”The EMBO Journal, 18(16):4535-4548 (1999).
Gozani et al., “Evidence that sequence-independent binding of highly conserved U2 snRNP proteins upstream of the branch site is required for assembly of spliceosomal complex A,”Genes&Development, 10:233-243 (1996).
Habets et al., “Mapping of B Cell Epitopes on Small Nuclear Ribonucleoproteins that React with Human Autoantibodies as well as with Experimentally-Induced Mouse Monoclonal Antibodies,”The Journal of Immunology, 143(8):2560-2566 (Oct. 15, 1989).
Halliday et al., “Differentiation of human tumors from nonmalignant tissue by natural-abundance13C NMR spectroscopy,”Magn. Reson. Med., 7(4):384-411 (1988).
Harper et al., “RNA binding specificity of aDrosophilasnRNP protein that shares sequence homology with mammalian U1-A and U2-B proteins,”Nucleic Acids Research, 20(14):3645-3650(1992).
Hong et al., “Association of U2 snRNO with the spliceosomal complex E,”Nucleic Acid Research, 25(2):354-361 (1997).
Jellum et al., “Profiling cells and body fluids—chromatography and two-dimensional electrophoresis as complementary techniques,”J. Chromatrogr., 488(1):105-127 (Mar. 17, 1989).
Jellum, E., “Multi-Component Analyses of Human Body Fluids and Tissues in Health and Disease Using Capillary Gas Chromatography -Mass Spectrometry and High-Resolution Two-dimensional Electrophoresis,”Journal of Chromatography, 239:29-37 (1982).
Jellum et al., “Clinical Applications of Two-Dimensional Electrophoresis,”Clin. Chem., 28(4):876-883 (1982).
Kramer et al., “Combined Biochemical and Electron Microscopic Analyses Reveal the Architecture of the Mammalian U2 snRNP,”The Journal of Cell Biology, 145(7):1355-1368 (Jun. 28, 1999).
Lalioti et al., “The Gene for Human U2 snRNP Auxiliary Factor Small 35-kDa Subunit (U2AF1) Maps to the Progressive Myoclonus Epilepsy (EPM1) Critical Region on Chromosome 21q22.3,”Genomics, 33:298-300 (1996).
Lamond et al., “Probing the Structure and Function of U2 snRNP with Antisense Oligonucleotides Made of 2'-OMe RNA,”Cell, 58:383-390 (Jul. 28, 1989).
Leaves et al., “Pyrolysis mass spectrometry in epidemiological and population genetic studies ofHaemophilus influenzae,”J. Med. Microbiol., 46(3):204-207 (1997).
Lim et al., “Altered hydroxylation of estrogen in patients with postmenopausal osteopenia,”J. Clin. Endocrinol. Metab., 82(4):1001-1006 (Apr. 1997).
Loo et al., “High sensitivity mass spectrometric methods for obtaining intact molecular weights from gel-separated proteins,”Electrophoresis, 20:743-748 (1999).
Lollo et al., “Improved two-dimensional gel electrophoresis representation of serum proteins by using ProtoClear™,”Electrophoresis, 20:854-859 (1999).
Ogorzalek Loo et al., “Sensitivity and mass accuracy for proteins analyzed directly from polyacrylamide gels: Implications for proteome mapping,”Electrophoresis, 18:382-390 (1997).
Ogorzalek Loo et al., “Mass Spectrometry of Proteins Directly from Polyacrylamide Gels,”Anal. C
Szaro Robert P.
Watkins Brynmor
Goodwin & Procter LLP
Harris Alana M.
Matritech, Inc.
LandOfFree
Materials and methods for detection and treatment of breast... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for detection and treatment of breast..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for detection and treatment of breast... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3439990